Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma

Hang Quach, Simon Benson, Helen Haysom, Anne Marie Wilkes, Nicole Zacher, Merrole Cole-Sinclair, Henry Miles Prince, Peter Mollee, Andrew Spencer, Phoebe Joy Ho, Simon J. Harrison, Cindy Lee, Bradley Augustson, James Daly

Research output: Contribution to journalArticleResearchpeer-review

Abstract

In recent years, the anti-CD38 monoclonal antibody daratumumab (Darzalex; Janssen-Cilag Pty Ltd) has been shown to be highly efficacious in relapsed and refractory multiple myeloma, with the final results of treatment in newly diagnosed patients awaited. Despite awareness of the potential interference of daratumumab in pre-transfusion immunohaematology testing during phase I and II clinical studies, there was a degree of unpreparedness in the community upon the introduction of this drug into the clinics, particularly the impact that it has on the operational processes in hospital transfusion laboratories and timely issue of red blood cells (RBCs). Anti-CD38 interference in pre-transfusion immunohaematology tests is a particular problem in patients being treated with daratumumab for multiple myeloma as many will require RBC transfusions during their disease treatment. Panagglutination caused by anti-CD38 monoclonal antibody during the indirect antiglobulin test may mask the presence of a clinically significant RBC alloantibody in the patient’s plasma during the antibody screen and identification process, which may be overlooked, particularly in urgent situations, subsequently resulting in a delayed or acute haemolytic transfusion reaction. Here, we summarise daratumumab’s effects on pre-transfusion immunohaematology testing and its impact on clinical practice and make practical recommendations based on a consensus from medical and scientific transfusion experts and myeloma specialists on behalf of the Australian and New Zealand Society of Blood Transfusion and Myeloma Scientific Advisory Group to Myeloma Australia, respectively.

Original languageEnglish
Pages (from-to)210-220
Number of pages11
JournalInternal Medicine Journal
Volume48
Issue number2
DOIs
Publication statusPublished - 1 Feb 2018

Keywords

  • daratumumab
  • immunohaematology
  • multiple myeloma
  • transfusion

Cite this

Quach, Hang ; Benson, Simon ; Haysom, Helen ; Wilkes, Anne Marie ; Zacher, Nicole ; Cole-Sinclair, Merrole ; Miles Prince, Henry ; Mollee, Peter ; Spencer, Andrew ; Joy Ho, Phoebe ; Harrison, Simon J. ; Lee, Cindy ; Augustson, Bradley ; Daly, James. / Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma. In: Internal Medicine Journal. 2018 ; Vol. 48, No. 2. pp. 210-220.
@article{ee32976b77a541faa9d9b4def32cb20c,
title = "Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma",
abstract = "In recent years, the anti-CD38 monoclonal antibody daratumumab (Darzalex; Janssen-Cilag Pty Ltd) has been shown to be highly efficacious in relapsed and refractory multiple myeloma, with the final results of treatment in newly diagnosed patients awaited. Despite awareness of the potential interference of daratumumab in pre-transfusion immunohaematology testing during phase I and II clinical studies, there was a degree of unpreparedness in the community upon the introduction of this drug into the clinics, particularly the impact that it has on the operational processes in hospital transfusion laboratories and timely issue of red blood cells (RBCs). Anti-CD38 interference in pre-transfusion immunohaematology tests is a particular problem in patients being treated with daratumumab for multiple myeloma as many will require RBC transfusions during their disease treatment. Panagglutination caused by anti-CD38 monoclonal antibody during the indirect antiglobulin test may mask the presence of a clinically significant RBC alloantibody in the patient’s plasma during the antibody screen and identification process, which may be overlooked, particularly in urgent situations, subsequently resulting in a delayed or acute haemolytic transfusion reaction. Here, we summarise daratumumab’s effects on pre-transfusion immunohaematology testing and its impact on clinical practice and make practical recommendations based on a consensus from medical and scientific transfusion experts and myeloma specialists on behalf of the Australian and New Zealand Society of Blood Transfusion and Myeloma Scientific Advisory Group to Myeloma Australia, respectively.",
keywords = "daratumumab, immunohaematology, multiple myeloma, transfusion",
author = "Hang Quach and Simon Benson and Helen Haysom and Wilkes, {Anne Marie} and Nicole Zacher and Merrole Cole-Sinclair and {Miles Prince}, Henry and Peter Mollee and Andrew Spencer and {Joy Ho}, Phoebe and Harrison, {Simon J.} and Cindy Lee and Bradley Augustson and James Daly",
year = "2018",
month = "2",
day = "1",
doi = "10.1111/imj.13707",
language = "English",
volume = "48",
pages = "210--220",
journal = "Internal Medicine Journal",
issn = "1444-0903",
publisher = "Wiley-Blackwell",
number = "2",

}

Quach, H, Benson, S, Haysom, H, Wilkes, AM, Zacher, N, Cole-Sinclair, M, Miles Prince, H, Mollee, P, Spencer, A, Joy Ho, P, Harrison, SJ, Lee, C, Augustson, B & Daly, J 2018, 'Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma' Internal Medicine Journal, vol. 48, no. 2, pp. 210-220. https://doi.org/10.1111/imj.13707

Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma. / Quach, Hang; Benson, Simon; Haysom, Helen; Wilkes, Anne Marie; Zacher, Nicole; Cole-Sinclair, Merrole; Miles Prince, Henry; Mollee, Peter; Spencer, Andrew; Joy Ho, Phoebe; Harrison, Simon J.; Lee, Cindy; Augustson, Bradley; Daly, James.

In: Internal Medicine Journal, Vol. 48, No. 2, 01.02.2018, p. 210-220.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma

AU - Quach, Hang

AU - Benson, Simon

AU - Haysom, Helen

AU - Wilkes, Anne Marie

AU - Zacher, Nicole

AU - Cole-Sinclair, Merrole

AU - Miles Prince, Henry

AU - Mollee, Peter

AU - Spencer, Andrew

AU - Joy Ho, Phoebe

AU - Harrison, Simon J.

AU - Lee, Cindy

AU - Augustson, Bradley

AU - Daly, James

PY - 2018/2/1

Y1 - 2018/2/1

N2 - In recent years, the anti-CD38 monoclonal antibody daratumumab (Darzalex; Janssen-Cilag Pty Ltd) has been shown to be highly efficacious in relapsed and refractory multiple myeloma, with the final results of treatment in newly diagnosed patients awaited. Despite awareness of the potential interference of daratumumab in pre-transfusion immunohaematology testing during phase I and II clinical studies, there was a degree of unpreparedness in the community upon the introduction of this drug into the clinics, particularly the impact that it has on the operational processes in hospital transfusion laboratories and timely issue of red blood cells (RBCs). Anti-CD38 interference in pre-transfusion immunohaematology tests is a particular problem in patients being treated with daratumumab for multiple myeloma as many will require RBC transfusions during their disease treatment. Panagglutination caused by anti-CD38 monoclonal antibody during the indirect antiglobulin test may mask the presence of a clinically significant RBC alloantibody in the patient’s plasma during the antibody screen and identification process, which may be overlooked, particularly in urgent situations, subsequently resulting in a delayed or acute haemolytic transfusion reaction. Here, we summarise daratumumab’s effects on pre-transfusion immunohaematology testing and its impact on clinical practice and make practical recommendations based on a consensus from medical and scientific transfusion experts and myeloma specialists on behalf of the Australian and New Zealand Society of Blood Transfusion and Myeloma Scientific Advisory Group to Myeloma Australia, respectively.

AB - In recent years, the anti-CD38 monoclonal antibody daratumumab (Darzalex; Janssen-Cilag Pty Ltd) has been shown to be highly efficacious in relapsed and refractory multiple myeloma, with the final results of treatment in newly diagnosed patients awaited. Despite awareness of the potential interference of daratumumab in pre-transfusion immunohaematology testing during phase I and II clinical studies, there was a degree of unpreparedness in the community upon the introduction of this drug into the clinics, particularly the impact that it has on the operational processes in hospital transfusion laboratories and timely issue of red blood cells (RBCs). Anti-CD38 interference in pre-transfusion immunohaematology tests is a particular problem in patients being treated with daratumumab for multiple myeloma as many will require RBC transfusions during their disease treatment. Panagglutination caused by anti-CD38 monoclonal antibody during the indirect antiglobulin test may mask the presence of a clinically significant RBC alloantibody in the patient’s plasma during the antibody screen and identification process, which may be overlooked, particularly in urgent situations, subsequently resulting in a delayed or acute haemolytic transfusion reaction. Here, we summarise daratumumab’s effects on pre-transfusion immunohaematology testing and its impact on clinical practice and make practical recommendations based on a consensus from medical and scientific transfusion experts and myeloma specialists on behalf of the Australian and New Zealand Society of Blood Transfusion and Myeloma Scientific Advisory Group to Myeloma Australia, respectively.

KW - daratumumab

KW - immunohaematology

KW - multiple myeloma

KW - transfusion

UR - http://www.scopus.com/inward/record.url?scp=85041393033&partnerID=8YFLogxK

U2 - 10.1111/imj.13707

DO - 10.1111/imj.13707

M3 - Article

VL - 48

SP - 210

EP - 220

JO - Internal Medicine Journal

JF - Internal Medicine Journal

SN - 1444-0903

IS - 2

ER -